The medication being studied is Etrasimod tablets, an oral drug taken at a dose of 2 mg. It is being investigated for its potential use in several immune-mediated inflammatory disorders, which are conditions where the immune system mistakenly attacks the body’s own tissues. Examples of these disorders include ulcerative colitis (a chronic inflammation of the colon), alopecia areata (patchy hair loss), atopic dermatitis (a type of eczema), and eosinophilic esophagitis (inflammation of the esophagus caused by certain white blood cells).
The purpose of the study is to compare how the medication is absorbed and processed in the body (known as PK, or pharmacokinetics) when blood samples are collected by the participant using a small fingertip device called a Tasso device versus when samples are taken by study staff. Healthy adult volunteers receive a single dose of the tablet, then use the Tasso device at home to collect tiny blood spots, and wear a small monitoring patch that records safety information such as heart rate and other vital signs. The study follows participants for a short period after the dose to check for any side effects and to ensure the medication is well tolerated.



Belgium